By Jaime Llinares Taboada
ImmuPharma PLC said Thursday that the U.S. Food & Drug Administration has approved the start of the pharmacokinetic study on its Lupuzor therapy for the treatment of lupus.
The biopharmaceutical company, which focuses on autoimmune diseases, metabolic diseases, anti-infectives and cancer, said the pharmacokinetic study will be used to assess the presence of Lupuzor in the body after administration of single dose.
The study will be carried out in 24 healthy men, and is expected to take between eight and 12 weeks to complete. Lupuzor will move into an optimized international Phase 3 trial following the successful completion of the pharmacokinetic study.
Pharmacokinetics refers to the study of how the body affects a drug.
Shares at 0749 GMT were flat at 8.62 pence, reversing gains earlier in the morning.
Write to Jaime Llinares Taboada at firstname.lastname@example.org; @JaimeLlinaresT
View more information: https://www.marketwatch.com/story/fda-approves-immupharma-pharmacokinetic-study-on-lupuzor-therapy-271628754825